ID   JC053-DR1
AC   CVCL_C5U0
DR   Wikidata; Q116049599
RX   PubMed=35724767;
CC   Population: Japanese.
CC   Selected for resistance to: ChEBI; CHEBI_75045; Dabrafenib (Tafinlar; GSK2118436).
CC   Sequence variation: Mutation; HGNC; HGNC:1097; BRAF; Simple; p.Val600Glu (c.1799T>A); ClinVar=VCV000013961; Zygosity=Heterozygous (PubMed=35724767).
CC   Sequence variation: Mutation; HGNC; HGNC:1097; BRAF; Unexplicit; Ex2-8del; Zygosity=Unspecified (PubMed=35724767).
CC   Derived from site: In situ; Colon, transverse; UBERON=UBERON_0001157.
DI   NCIt; C96156; Colorectal neuroendocrine carcinoma
DI   ORDO; Orphanet_100080; Neuroendocrine tumor of the colon
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
HI   CVCL_C5TZ ! JC053
SX   Male
AG   21Y
CA   Cancer cell line
DT   Created: 15-12-22; Last updated: 19-12-24; Version: 4
//
RX   PubMed=35724767; DOI=10.1016/j.canlet.2022.215799;
RA   Shimizu Y., Maruyama K., Suzuki M., Kawachi H., Low S.-K., Oh-hara T.,
RA   Takeuchi K., Fujita N., Nagayama S., Katayama R.;
RT   "Acquired resistance to BRAF inhibitors is mediated by BRAF splicing
RT   variants in BRAF V600E mutation-positive colorectal neuroendocrine
RT   carcinoma.";
RL   Cancer Lett. 543:215799.1-215799.9(2022).
//